AdventHealthMD
A recent study, called FLOW, showed Ozempic had dramatic results in slowing chronic kidney disease progression in participants with Type 2 diabetes.
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
The new SMILE with Stella Tremonti Down Syndrome Clinic is the only lifespan program of its kind in the Southeast.
The accreditation recognizes the hospital’s commitment to excellence in patient care and safety.
Our website uses cookies. Please review our privacy policy to find out more about the cookies we use. Browsing our website means you accept these terms.